GMAB vs TECH: fair value comparison
Genmab A/S and Bio-Techne Corporation · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, GMAB currently sits closer to the top of our discount ranking.
| GMAB | TECH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $28.68 | $72.43 |
| 12-month range | $25.45–$33.27 | $50.79–$72.18 |
| Sector rank | #48 of 113 Healthcare | #49 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: GMAB fair value analysis · TECH fair value analysis